$ALKS
Alkermes plc. Stock $alks

$alks Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913079467 Filed on October 31, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2013 Q1
Revenue	$154.5M	$139.8M	$163.4M
YoY Change	13.68%	12.76%	25.23%
Cost Of Revenue	$42.90M	$45.42M	$47.99M
YoY Change	10.24%	9.48%	-6.08%
Gross Profit	$111.6M	$94.38M	$115.4M
YoY Change	15.06%	14.42%	45.38%
Gross Profit Margin	72.23%	67.51%	70.63%
Selling, General & Admin	$44.20M	$39.45M	$34.68M
YoY Change	47.99%	25.54%	-10.62%
% of Gross Profit	39.61%	41.8%	30.04%
Research & Development	$48.70M	$45.95M	$35.80M
YoY Change	55.5%	30.95%	-20.8%
% of Gross Profit	43.64%	48.68%	31.01%
Depreciation & Amortization	$23.40M	$23.70M	$18.32M
YoY Change	25.81%	26.06%	-11.06%
% of Gross Profit	20.97%	25.11%	15.87%
Operating Expenses	$105.7M	$85.40M	$70.48M
YoY Change	72.75%	28.39%	-26.28%
Operating Profit	$5.900M	-$3.878M	$18.98M
YoY Change	-76.64%	-171.5%	-217.19%
Interest Expense		$3.477M	$11.47M
YoY Change		-84.65%	-217.07%
% of Operating Profit			60.44%
Other Income/Expense, Net	-$3.000M	-$3.651M	-$11.12M
YoY Change	-34.74%	-83.18%	3606.0%
Pretax Income	$2.900M	-$7.529M	$7.866M
YoY Change	-85.97%	-53.77%	-111.6%
Income Tax	-$15.20M	$233.0K	$4.867M
% Of Pretax Income	-524.14%		61.87%
Net Earnings	$18.10M	-$7.800M	$3.000M
YoY Change	11.04%	-53.29%	-104.73%
Net Earnings / Revenue	11.72%	-5.58%	1.84%
Basic Earnings Per Share		-$0.06	$0.02
Diluted Earnings Per Share	$0.12	-$0.06	$0.02
COMMON SHARES
Basic Shares Outstanding	136.8M shares	136.1M shares	133.3M shares
Diluted Shares Outstanding		136.1M shares	139.7M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$362.2M	$339.4M	$221.4M
YoY Change	73.06%	70.18%	16.23%
Cash & Equivalents	$167.6M	$173.5M	$96.96M
Short-Term Investments	$194.7M	$165.9M	$124.4M
Other Short-Term Assets	$27.50M	$23.00M	$19.10M
YoY Change	116.54%	82.54%	51.59%
Inventory	$46.22M	$40.71M	$43.48M
Prepaid Expenses
Receivables	$134.2M	$120.4M	$124.6M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$570.1M	$523.6M	$408.6M
YoY Change	47.12%	47.52%	20.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$274.5M	$274.4M	$288.4M
YoY Change	-6.06%	-7.11%	-4.81%
Goodwill	$92.74M	$92.74M	$92.74M
YoY Change		0.0%	0.0%
Intangibles	$537.6M	$550.4M	$576.0M
YoY Change	-8.31%	-7.78%	-6.77%
Long-Term Investments	$87.80M	$55.80M	$82.80M
YoY Change	192.67%	541.38%	48.65%
Other Assets	$14.89M	$15.50M	$21.71M
YoY Change	-35.32%	-29.28%	-18.98%
Total Long-Term Assets	$1.007B	$988.9M	$1.062B
YoY Change	-1.64%	-2.64%	-3.13%
TOTAL ASSETS
Total Short-Term Assets	$570.1M	$523.6M	$408.6M
Total Long-Term Assets	$1.007B	$988.9M	$1.062B
Total Assets	$1.578B	$1.512B	$1.470B
YoY Change	11.75%	10.35%	2.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.49M	$12.12M	$18.28M
YoY Change	35.36%	-22.22%	-0.64%
Accrued Expenses	$71.70M	$52.20M	$58.60M
YoY Change	34.52%	21.96%	-3.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.750M	$6.750M	$6.750M
YoY Change	0.0%	0.0%	117.74%
Total Short-Term Liabilities	$100.9M	$73.72M	$85.93M
YoY Change	30.56%	7.24%	-3.63%
LONG-TERM LIABILITIES
Long-Term Debt	$357.5M	$359.1M	$362.3M
YoY Change	-1.33%	-1.3%	-17.92%
Other Long-Term Liabilities	$12.58M	$17.49M	$23.26M
YoY Change	24.26%	65.89%	165.8%
Total Long-Term Liabilities	$370.1M	$376.6M	$385.5M
YoY Change	-0.63%	0.59%	-14.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$100.9M	$73.72M	$85.93M
Total Long-Term Liabilities	$370.1M	$376.6M	$385.5M
Total Liabilities	$512.4M	$495.5M	$517.9M
YoY Change	4.18%	2.04%	-10.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$482.3M	-$500.4M	-$499.9M
YoY Change	-4.11%	-3.63%	-4.76%
Common Stock	$1.555B	$1.526B	$1.460B
YoY Change	8.65%	8.17%	5.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$17.83M	$14.40M	$5.380M
YoY Change	231.78%	269.9%	842.21%
Treasury Stock Shares	689.9K shares	596.4K shares	313.5K shares
Shareholders Equity	$1.065B	$1.017B	$952.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.578B	$1.512B	$1.470B
YoY Change	11.75%	10.35%	2.44%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2013 Q1
OPERATING ACTIVITIES
Net Income	$18.10M	-$7.800M	$3.000M
YoY Change	11.04%	-53.29%	-104.73%
Depreciation, Depletion And Amortization	$23.40M	$23.70M	$18.32M
YoY Change	25.81%	26.06%	-11.06%
Cash From Operating Activities	$38.10M	$41.40M	$55.40M
YoY Change	45.42%	-16.7%	262.09%
INVESTING ACTIVITIES
Capital Expenditures	-$9.900M	-$5.600M	$8.259M
YoY Change	253.57%	24.44%	-200.72%
Acquisitions
YoY Change
Other Investing Activities	-$47.40M	$2.900M	-$103.5M
YoY Change	65.73%	-95.86%	666.67%
Cash From Investing Activities	-$57.30M	-$2.700M	-$111.8M
YoY Change	83.07%	-104.12%	417.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$1.688M
YoY Change
Cash From Financing Activities	13.20M	18.40M	17.60M
YoY Change	53.49%	-126.86%	291.11%
NET CHANGE
Cash From Operating Activities	38.10M	41.40M	55.40M
Cash From Investing Activities	-57.30M	-2.700M	-111.8M
Cash From Financing Activities	13.20M	18.40M	17.60M
Net Change In Cash	-6.000M	57.10M	-38.80M
YoY Change	-271.43%	22.01%	2055.56%
FREE CASH FLOW
Cash From Operating Activities	$38.10M	$41.40M	$55.40M
Capital Expenditures	-$9.900M	-$5.600M	$8.259M
Free Cash Flow	$48.00M	$47.00M	$47.14M
YoY Change	65.52%	-13.28%	100.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Use of Estimates</font></i></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates and judgments and methodologies, including those related to revenue recognition and related allowances, its collaborative relationships, clinical trial expenses, the valuation of inventory, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and derivative instruments, litigation and restructuring charges. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.</font></p> <p style="TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt;"> </p> </div>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2013Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	14771000	USD
CY2013Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13842000	USD
CY2013Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13059000	USD
CY2013Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	16135000	USD
CY2013Q1	alks	Marketable Securities At Amortized Cost MarketableSecuritiesAtAmortizedCost	207361000	USD
CY2013Q3	alks	Marketable Securities At Amortized Cost MarketableSecuritiesAtAmortizedCost	213780000	USD
CY2013	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	64000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	8190000	USD
CY2013Q1	alks	Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	45000	USD
CY2013Q3	alks	Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	78000	USD
CY2013Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	207218000	USD
CY2013Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	221736000	USD
CY2013Q1	alks	Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	162000	USD
CY2013Q3	alks	Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	156000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	56400000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	185392000	USD
	alks	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	15000	USD
	alks	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	273000	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	86899000	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	115748000	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Maturities Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost	202647000	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	86938000	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	115613000	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	202551000	USD
CY2013Q3	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	1200000	USD
CY2013Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	1200000	USD
CY2013Q3	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	1200000	USD
CY2013Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	13506000	USD
	alks	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Number Of Investments Transfers From Level2to Level1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisNumberOfInvestmentsTransfersFromLevel2toLevel1	0	item
CY2013Q3	us-gaap	Goodwill Gross GoodwillGross	92740000	USD
CY2013Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12878000	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	43483000	USD
CY2013Q3	us-gaap	Inventory Net InventoryNet	40708000	USD
CY2013Q1	alks	Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider	600000	USD
CY2013Q3	alks	Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider	1800000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	40000000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	60000000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	410728000	USD
CY2013Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	122293000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	288435000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	417991000	USD
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	143614000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	274377000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	18282000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	12124000	USD
CY2013Q1	us-gaap	Due To Employees Current DueToEmployeesCurrent	30432000	USD
CY2013Q3	us-gaap	Due To Employees Current DueToEmployeesCurrent	17727000	USD
CY2013Q1	us-gaap	Interest Payable Current InterestPayableCurrent	970000	USD
CY2013Q3	us-gaap	Interest Payable Current InterestPayableCurrent	934000	USD
CY2013Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	27226000	USD
CY2013Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	1200000	USD
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	33497000	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	76910000	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	64282000	USD
CY2013Q2	us-gaap	Quantifying Misstatement In Current Year Financial Statements Amount QuantifyingMisstatementInCurrentYearFinancialStatementsAmount	1000000	USD
	alks	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Number Of Investments Transfer From Level1 To Level2 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisNumberOfInvestmentsTransferFromLevel1ToLevel2	0	item
CY2013Q3	us-gaap	Goodwill Goodwill	92740000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	640600000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	90179000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	550421000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25572000	USD
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	65000000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	70000000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	70000000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	1200000	USD
CY2013Q1	us-gaap	Long Term Debt LongTermDebt	369008000	USD
CY2013Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	6750000	USD
CY2013Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	362258000	USD
CY2013Q3	us-gaap	Long Term Debt LongTermDebt	365872000	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	6750000	USD
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	359122000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	600000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	600000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14209000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10447000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23018000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18609000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7762000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16707000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-428000	USD
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	131067000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1470291000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	1016977000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1512437000	USD
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	131067000	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5726000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130753000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135589000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	136106000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4836000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	136106000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135358000	shares
CY2013Q3	us-gaap	Assets Current AssetsCurrent	523580000	USD
CY2013Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	550421000	USD
CY2013Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	55815000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15504000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135358000	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10470000	shares
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11224000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10221000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6472000	shares
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	233000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2951000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	422000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1186000	USD
	dei	Entity Registrant Name EntityRegistrantName	Alkermes plc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001520262
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	136762382	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96961000	USD
CY2013Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	124391000	USD
CY2013Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	124620000	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19133000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	408588000	USD
CY2013Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	575993000	USD
CY2013Q1	us-gaap	Goodwill Goodwill	92740000	USD
CY2013Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	82827000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21708000	USD
CY2013Q1	us-gaap	Assets Assets	1470291000	USD
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2270000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	85930000	USD
CY2013Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8866000	USD
CY2013Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	37603000	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23260000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	517917000	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	1338000	USD
CY2013Q1	us-gaap	Treasury Stock Value TreasuryStockValue	5380000	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1458857000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2518000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-499923000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	952374000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7128000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2523000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	8099000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	23018000	USD
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	134065107	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	137242939	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	133751610	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	136646516	shares
CY2013Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	313497	shares
CY2013Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	596423	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2012Q3	alks	Manufacturing And Royalty Revenues ManufacturingAndRoyaltyRevenues	107327000	USD
CY2012Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15192000	USD
CY2012Q3	us-gaap	Contracts Revenue ContractsRevenue	1459000	USD
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	123978000	USD
CY2012Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	41491000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35088000	USD
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31428000	USD
CY2012Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10547000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	118554000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	5424000	USD
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	216000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	22648000	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	723000	USD
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21709000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16285000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2012Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-463000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	594000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16576000	USD
	alks	Manufacturing And Royalty Revenues ManufacturingAndRoyaltyRevenues	245707000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	27564000	USD
	us-gaap	Contracts Revenue ContractsRevenue	2946000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	276217000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	83561000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72894000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61212000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20981000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	238648000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	37569000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	515000	USD
	us-gaap	Interest Expense InterestExpense	32818000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1646000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30657000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	6912000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-604000	USD
	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	522000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5644000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	139802000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	143680000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3651000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7529000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	8506000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47401000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	744000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Sales Revenue Net SalesRevenueNet	278433000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	268782000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	9651000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7671000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3878000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36829000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18609000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	387000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-944000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12129000	USD
	alks	Prepayment Of Penalty On Debt Refinancing PrepaymentOfPenaltyOnDebtRefinancing	2800000	USD
	alks	Payment Of Instrument Principal Attributable To Original Issue Discount PaymentOfInstrumentPrincipalAttributableToOriginalIssueDiscount	2657000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	4385000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	5617000	USD
	alks	Increase Decrease In Inventory Prepaid Expenses And Other Assets IncreaseDecreaseInInventoryPrepaidExpensesAndOtherAssets	3111000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-17422000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2060000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2368000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	45048000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11206000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	17000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	99218000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	74985000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	9731000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	387000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	368557000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3323000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	446568000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-71216000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	48817000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	54115000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8071000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8524000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3375000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1. THE COMPANY</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The Company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address CNS disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes has an R&D center in Waltham, Massachusetts; R&D and manufacturing facilities in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio.</font></p> </div>
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	173505000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83601000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132418000	USD
CY2013Q2	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	3000000	USD
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2685000	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	165921000	USD
CY2013Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	120448000	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22998000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	1369000	USD
CY2013Q3	us-gaap	Treasury Stock Value TreasuryStockValue	14404000	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1524783000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5580000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-500351000	USD
CY2013Q3	alks	Manufacturing And Royalty Revenues ManufacturingAndRoyaltyRevenues	118571000	USD
CY2013Q3	us-gaap	Assets Assets	1512437000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	73717000	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17486000	USD
CY2013Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	36014000	USD
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9121000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	495460000	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	19227000	USD
CY2013Q3	us-gaap	Contracts Revenue ContractsRevenue	2004000	USD
	alks	Manufacturing And Royalty Revenues ManufacturingAndRoyaltyRevenues	238359000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	36606000	USD
	us-gaap	Contracts Revenue ContractsRevenue	3468000	USD
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	45423000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45947000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39454000	USD
CY2013Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12856000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	91414000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79409000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	72387000	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	295000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	3477000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-469000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	456000	USD
	us-gaap	Interest Expense InterestExpense	6945000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-639000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	8456000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1516000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	1773000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-4172000	USD
	alks	Increase Decrease In Inventory Prepaid Expenses And Other Assets IncreaseDecreaseInInventoryPrepaidExpensesAndOtherAssets	3706000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7727000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	670000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1086000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9198000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	54088000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	33943000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	8456000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	30500000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	76544000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	1184000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	834000	USD
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1191000	USD
	us-gaap	Restructuring Reserve Translation Adjustment RestructuringReserveTranslationAdjustment	300000	USD
CY2013Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	807000	USD
CY2013Q3	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	3000000	USD
	alks	Fair Value Measurement Conversion Of Investment From Cost Method Investments To Availableforsale Securities FairValueMeasurementConversionOfInvestmentFromCostMethodInvestmentsToAvailableforsaleSecurities	807000	USD
	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	3000000	USD

Files In Submission

Name	View Source	Status
R42.htm	Edgar Link	pending
0001104659-13-079467-index-headers.html	Edgar Link	pending
0001104659-13-079467-index.html	Edgar Link	pending
0001104659-13-079467.txt	Edgar Link	pending
0001104659-13-079467-xbrl.zip	Edgar Link	pending
a13-19836_110q.htm	Edgar Link	pending
a13-19836_1ex31d1.htm	Edgar Link	pending
a13-19836_1ex31d2.htm	Edgar Link	pending
a13-19836_1ex32d1.htm	Edgar Link	pending
alks-20130930.xml	Edgar Link	completed
alks-20130930.xsd	Edgar Link	pending
alks-20130930_cal.xml	Edgar Link	unprocessable
alks-20130930_def.xml	Edgar Link	unprocessable
alks-20130930_lab.xml	Edgar Link	unprocessable
alks-20130930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALKS
Alkermes plc. Stock $alks

2013 Q4 Form 10-Q Financial Statement

#000110465913079467 Filed on October 31, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALKS Alkermes plc. Stock $alks

2013 Q4 Form 10-Q Financial Statement

#000110465913079467 Filed on October 31, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALKS
Alkermes plc. Stock $alks